Bridgeway Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bridgeway Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-135,500	Closed	-$534K	–	1343
2021 Q4	$534K	Sell	135,500 -244,592	-64%	-$1.19M	0.01%	965
2021 Q3	$1.83M	Sell	380,092 -20,000	-5%	-$82.1K	0.03%	656
2021 Q2	$1.84M	Sell	400,092 -74,500	-16%	-$359K	0.03%	653
2021 Q1	$2.79M	Sell	474,592 -353,600	-43%	-$2.45M	0.05%	479
2020 Q4	$2.83M	Buy	828,192 +429,800	+108%	+$820K	0.06%	387
2020 Q3	$574K	Hold	398,392	–	–	0.01%	838
2020 Q2	$795K	Buy	398,392 +104,792	+36%	+$205K	0.02%	729
2020 Q1	$573K	Buy	+293,600	New	+$874K	0.01%	720

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's LXRX Position: Q1 2022 in Review

Bridgeway Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2022, closing a stake of 135,500 shares — an estimated $534K sold.

Bridgeway Capital Management first reported a position in LXRX in Q1 2020 and held it in 8 quarters. The position peaked at $2.83M in Q4 2020. 101 funds tracked by Wall St. Rank hold LXRX as of Q1 2022.

Bridgeway Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Bridgeway Capital Management sold 135,500 Lexicon Pharmaceuticals shares in Q1 2022, an estimated $534K.
Bridgeway Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Bridgeway Capital Management's Lexicon Pharmaceuticals position peaked at $2.83M in Q4 2020.
101 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2022.

Based on Bridgeway Capital Management's 13F filing for Q1 2022, filed 16 May 2022.